Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. März 2017 08:00 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy

SAN DIEGO, March 13, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
09. März 2017 16:01 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2016 Financial Results

SAN DIEGO, March 09, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
02. März 2017 16:01 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics to Highlight Natural Killer Cell Programs and Engineered Pluripotent Cell Platform for Off-the-Shelf Cancer Immunotherapy at the 2017 AACR Annual Meeting

SAN DIEGO, March 02, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
01. März 2017 16:01 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics to Present at Two Upcoming Conferences in March

SAN DIEGO, March 01, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...
27. Februar 2017 08:00 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics and Regents of the University of Minnesota Expand Research Collaboration for Clinical Translation of Engineered iPSC-Derived Natural Killer Cell Cancer Immunotherapy

Off-the-Shelf Natural Killer Cell Therapy Being Developed to Complement Standard-of-Care Monoclonal Antibody Treatment for Cancer First-of-Kind Product Candidate to be Manufactured from an...
08. Februar 2017 16:01 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare Conference

SAN DIEGO, Feb. 08, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
05. Januar 2017 08:00 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics Announces First Patient Treated in ProTmune™ PROTECT Clinical Trial for the Prevention of Graft-Versus-Host Disease

SAN DIEGO, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
22. November 2016 08:00 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics Announces Private Financing

SAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...
07. November 2016 16:01 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics Reports Third Quarter 2016 Financial Results

IND Filed for FATE-NK100 Adaptive Natural Killer Cell Immunotherapy in Acute Myeloid Leukemia Orphan Drug Designations for ProTmune Granted by FDA and EMA ProTmune™ PROTECT Clinical Protocol...
03. November 2016 16:59 ET | Quelle: Fate Therapeutics, Inc.

Fate Therapeutics Announces Oral Presentation on Natural Killer Cell Product Candidate FATE-NK100 at the 2016 ASH Annual Meeting

SAN DIEGO, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and...

Vorherige Seite